In conclusion, our results demonstrated that exosomal miR-301a-3p could be used as a non-invasive biomarker to indicate trastuzumab response, which was maybe a novel treating target to reduce trastuzumab resistance and improve the curative effect of trastuzumab in HER2-positive GC patients. This evidence concerns the gene ERBB2 and gastric cancer.